- Home
- Media Center
- Press releases
- Innovative Medicine
Innovative Medicine
Landmark Study Shows that Adding Rivaroxaban to Standard Antiplatelet Therapy Significantly Reduced Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome
Rivaroxaban Used in Combination with Standard Therapy Reduced Cardiovascular Death by Over 30%
Janssen Pharmaceutical Companies Launch Healthy Minds Initiative to Spur Neuroscience Collaboration and Support Millions Suffering from Brain Disorders
Healthy Minds Brings Together Researchers and Data to Solve Mysteries of the Brain, Commits Key Research Programs to Public Sector, and Addresses Stigma
New Sirukumab (CNTO 136) Phase 2 Data Show Efficacy of Interleukin-6 Inhibitor across Multiple Dose Regimens in Treatment of Rheumatoid Arthritis
Subcutaneously Administered Monoclonal Antibody Improved Signs and Symptoms and Reduced Inflammation in Patients with Active Rheumatoid Arthritis
INCIVO® (telaprevir) Demonstrates Efficacy and Increased Cure Rates among Cirrhotic Patients with Genotype-1 Chronic HCV Compared to Standard of Care
Data presented at AASLD 2011 highlights efficacy in typically hard to treat patients
Tibotec To Present Final Safety And Efficacy Results From Phase 2b PILLAR Study Of Once-Daily TMC435 In Late-Breaker At AASLD
Data Show High Rates Of Virologic Response And Shortened Treatment Duration; Safety And Tolerability Comparable To Placebo
FDA Approves XARELTO® (Rivaroxaban) To Reduce The Risk Of Stroke And Systemic Embolism In Patients With Nonvalvular Atrial Fibrillation
XARELTO® Combines Proven Effectiveness And Demonstrated Safety Profile With Convenient, Once-Daily Dosing